Skip to content

A Clinical Study on S2-M1 ccPAS for Improving Upper Limb Motor Function in Stroke

A Clinical Study on S2-M1 ccPAS for Improving Upper Limb Motor Function in Stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115649
Enrollment
Unknown
Registered
2025-12-29
Start date
2025-12-31
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Active S2-M1 ccPAS group:The stimulation targets for S2 and M1 were determined based on the relative positions of the cap electrodes over the corresponding brain regions, identified through visual obs
sham S2-M1 ccPAS group:The ccPAS sham stimulation protocol was set up identically to the experimental group, except that the coil was held at a 90° angle to the head, with only one edge placed against

Sponsors

Shanghai Guanghua Hospital of Integrative Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Healthy adults aged 40-80 years with an educational level of junior high school or above; 2. First-ever stroke with a disease duration within 1 year; 3. Stroke lesion located in a unilateral cerebral hemisphere or the brainstem, presenting with unilateral hemiplegia; 4. Patients with stable vital signs, clear consciousness, and able to cooperate with relevant examinations and treatments; 5. Presence of unilateral upper limb motor dysfunction, with upper limb function at Brunnstrom stage >= II; 6. Patients or their guardians voluntarily agree to participate in and cooperate with this study and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Any contraindications to transcranial magnetic stimulation, such as the presence of metallic implants, pacemakers, or other foreign objects in the body; 2. Transient ischemic attack, recurrent stroke, primary or secondary intracerebral hematoma, subarachnoid hemorrhage, or subdural/epidural hematoma; 3. Lesions involving the stimulation target sites (M1 hand area, S2 region); 4. Severe impairment of consciousness or communication (e.g., severe visual, hearing, speech, or cognitive impairments); 5. History of psychiatric disorders, epilepsy, or current use of antiepileptic therapy; 6. Severe visceral diseases affecting the liver, lungs, heart, kidneys, or other organs; 7. History of substance addiction related to drugs, alcohol, tobacco, or other addictive substances; 8. Other conditions that may cause motor dysfunction, such as Parkinson's disease, peripheral neuropathy, brain tumors, abscesses, or spinal cord diseases.

Design outcomes

Primary

MeasureTime frame
Fugl-Meyer assessment of the upper extremity;

Secondary

MeasureTime frame
Brunnstrom Motor Function Staging Assessment for Hemiplegia;Wolf motor function test, WMFT;Modified Barthel Index;Stroke Specific Quality of Life;FMRI indices;

Countries

China

Contacts

Public ContactLu Hongyuan

Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine

871332192@qq.com+86 181 1732 4922

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026